Video Author: Mary Jo Dales Publish date: June 6, 2016
News Author: Mary Jo Dales Publish date: June 4, 2016
Lenalidomide maintenance therapy significantly prolonged overall survival after autologous stem cell transplant in newly diagnosed multiple myeloma pa...
News Author: Mary Jo Dales Publish date: June 4, 2016
Upfront high-dose melphalan and autologous stem cell transplantation was superior to bortezomib-melphalan-prednisone for fit patients under age 65 wit...
News Author: Mary Jo Dales Publish date: June 1, 2016
News Author: Mary Jo Dales Publish date: May 26, 2016
Key clinical point: Venetoclax can achieve responses in patients who are refractory to ibrutinib.
Major finding: The overall response rate was 61%...
Video Author: Mary Jo Dales Publish date: April 27, 2016
Key clinical point: Adding ixazomib to lenalidomide and dexamethasone was associated with a longer progression-free survival and limited additiona...
News Author: Mary Jo Dales Publish date: April 27, 2016
Key clinical point: Chronic lymphocytic leukemia cells can be identified at levels as low as 0.0010% with a newly developed and validated single-t...
News Author: Mary Jo Dales Publish date: April 15, 2016
Key clinical point: Weekly and 14-day prophylaxis regimens with rIX-FP were well tolerated and provided low bleeding rates and target joint improv...
News Author: Mary Jo Dales Publish date: April 14, 2016
Key clinical point: Prelabor cesarean delivery was associated with an increased risk of childhood ALL, but not AML.
Major finding: The odds ratio ...
News Author: Mary Jo Dales Publish date: April 13, 2016
News Author: Mary Jo Dales Publish date: April 13, 2016
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had myelody...
News Author: Mary Jo Dales Publish date: April 13, 2016
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had myelody...
News Author: Mary Jo Dales Publish date: April 12, 2016
Key clinical point: Using FDG-PET imaging to gauge treatment response after the first two rounds of ABVD therapy helps to determine which patients...
News Author: Mary Jo Dales Publish date: April 12, 2016
Key clinical point: The CUDC-907 dose to be used in phase II studies will be 60 mg on a 5-days-on/2-days-off dosing schedule. Major finding: Two co...
News Author: Mary Jo Dales Publish date: April 11, 2016
